Skip to NavigationSkip to content


Sanofi plans R&D jobs cuts in France

Sanofi chief executive Olivier Brandicourt

Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across the firm’s base in France, as he pushes ahead with a global restructure of the company.

Bloomberg reports that Sanofi has told French labour unions that it plans to make up to 600 job losses, in the form of voluntary redundancies.

Counting the true cost of the Cancer Drugs Fund cuts

Published on 14/09/15 at 11:12am
Pharma companies say that cuts to cancer treatments could affect clinical trials

Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs Fund, which saw 17 medicines for 25 indications removed from the scheme.  

Among the casualties were Roche’s breast cancer drug Kadcyla (trastuzumab emtansine), and Avastin (bevacizumab) for cervical, breast and bowel cancers, plus Celgene’s pancreatic cancer treatment Abraxane (paclitaxel) and melanoma drugs Revlimid (lenalidomide) and Imnovid (pomalidomide).

Companies braced for new round of cancer cuts

NHS sign
NHS England is cutting treatments from the over-budget Cancer Drugs Fund

Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund from November 1st in the latest round of NHS cuts to hit patients.

As many as 10,000 patients are expected to be affected by the decision to remove treatments from the list NHS England funds for end of life treatments, through the controversial scheme.

GSK sees further US job losses following Novartis deal

GSK image

Hundreds more jobs are at risk within GlaxoSmithKline as the fallout from the company’s asset-swapping deal with Novartis continues.

Staff in the UK firm’s consumer health division in Pittsburgh, Pennsylvania, have been told their jobs are at risk – after the firm decided to close the office where 275 members of the workforce are based.

Eisai cuts 25% of US staff

Eisai image

Eisai’s US business is offloading around 200 jobs as part of some restructuring to create a more ‘efficient and focussed organisation’.

The job losses are expected to take place in May and US divisions up for the chop include R&D, manufacturing, sales and marketing, plus administrative departments. However, the Japanese-based firm has said that it does not have plans to close any of its main offices or facilities.

Daiichi Sankyo cuts 16% of US staff

Daiichi image

Daiichi Sankyo is laying off 16% of its staff at its US commercial headquarters as the company braces itself for upcoming loss of exclusivity on big drugs.

Over the next two years the Japanese firm will face generic competition for two of its biggest products – blood pressure medicine Benicar (olmesartan), which accounted for 27% of Daiichi’s turnover last year with $2.6 billion in sales, and cholesterol drug Welchol (colesevelam).

GSK China scandal leads to staff conflict

GSK image

Around 135 workers who face being removed from their posts by GlaxoSmithKline due to misconduct centering on bribery scandals in China plan to dispute the decision.

GSK has confirmed it took disciplinary action against staff whose conduct contravened its values and code of conduct, but has not specified the numbers involved. Although it wasn’t long ago that the firm was responding to rumours of unrest and denying jobs cuts in China.

GSK cancels sale of established products

GSK image

GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems.

The pharma giant began considering the divestment in July after its disappointing second quarter results. Since then it says it has received a number of bids from various firms.

“The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products,” GSK says in a statement.

Teva to ditch R&D in cancer and women’s health

Teva image

Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and its core therapeutic areas in respiratory and drugs for the central nervous system.

The Israeli drugmaker, the world’s biggest producer of copycat medicines, says it will discontinue or divest a total of 14 projects in its pipeline, according to a statement.

Boehringer to slash 600 jobs in native Germany

Boehringer image

Boehringer Ingelheim is to cut around 600 of its staff in Germany as part of a drive to reduce costs in in its native land by €450 million ($580 million).

The privately-owned German firm says it is being forced into axing staff because of both healthcare budget cuts in the US and the effects of the restrictive AMNOG drug pricing scheme in Germany, which is squeezing sales of Boehringer’s medicines.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches